anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:A stable cleatine amidinohydrolase pharmaceutical containing a nonionic surfactant, etc. having >=14 hydrophilic-lipophilic balance (HLB) as a stabilizer without causing the deterioration nor clouding even in preservation in the form of a solution. CONSTITUTION:A cleatine amidinohydrolase pharmaceutical containing within 0.01-1,000mg range based on 100 units cleatine amidinohydrolase one or more stabilizers selected from the group consisting of a nonionic surfactant, e.g. polyoxyethylene alkyl phenyl ether or polyoxyethylene acyl ester, having >=14 hydrophilic-lipophilic balance (HLB) a chelating agent, e.g. ethylenediaminetetraacetic acid, and a preservative, e.g. azide, antibiotic substance and sulfamide agent therein.
Receives the same dosage of Risperidone. Placebo is given to this group in same form and appearance as MS14 in the other arm of the study.
The control period includes a period whereby clinicians will not have access to ETO2 monitoring and routine RSI practices will be documented including all study variables. At all institutions, RSI is performed in a similar manner, utilising an airway checklist. There is no 'standard operating procedure' for RSI in any of the EDs and methods, therefore, vary depending on clinician preference and the condition of the patient, however, each site is a tertiary-level, university teaching hospital and therefore clinical practice is up to date and evidence-based. Standard preoxygenation methods in the Emergency department often consist of a bag-valve mask, with or without a PEEP valve, set at 15L/min, or the use of non-invasive ventilation or a non-rebreather mask, with or without a nasal cannula, set at 15 L/min or flush rate oxygen (\>40 L/min). US sites have access to high-flow (\>30L/min) oxygen. This is the only difference in the preoxygenation method.
Radical cystoprostatectomy (RCP) is the standard treatment of muscle invasive, and refractory high grade, superficial bladder cancer. RCP involves the removal of the bladder and prostate. While this is an effective treatment for patients with organ confined disease almost all men following RCP are impotent due to resection of the neurovascular bundles that control erectile dysfunction. While neobladders (new bladders formed out of detubularized bowel connected to the native urethra) allow patients to void normally, many of these patients have difficulty with urinary incontinence. Two modifications have been developed to improve the functional outcomes of this surgery. Nerve sparing cystectomy (NSC) attempts to spare the cavernosal nerves that travel immediately adjacent to the lateral prostate and are routinely divided during a standard RCP. Published series of NSC have shown improved preservation of sexual function and less urinary incontinence without compromising cancer control. Another alternative, prostate capsule sparing cystectomy (PCSC), removes the adenoma and prostatic urethra along with the urinary bladder, but leaves in situ the prostatic capsule and subsequently the surrounding neurovascular bundle. Several retrospective series have demonstrated preservation of sexual function and improved urinary continence compared to standard RCP and neobladder. A concern with PCSC is that prostate or urothelial cancer invading the prostate could be left behind with preservation of the prostate capsule. Most reported series in which patients were screened with digital rectal exam, prostate and prostatic urethral biopsy, and PSA blood testing could identify patients at risk for having prostate or urothelial cancer in the prostate capsule preoperatively to recommend an alternative approach. Therefore, both NSC and PCSC appear to offer better urinary and sexual function in properly selected patients over conventional RCP in retrospective series. However, these procedures have not been evaluated prospectively in a randomized fashion. Our intent is to evaluate the functional outcomes of PCSC and NSC with orthotopic neobladder in terms of urinary and sexual function using the bladder cancer index, a validated quality of life instrument, and determine the surgical margin status, and complications of the two surgical techniques.
Participants will first receive a placebo (saline) nerve block injection. Pain sensitivity and any reported sensory or motor changes will be assessed 60 minutes post-injection using a Numerical Rating Scale (NRS). After a washout period, participants will cross over to receive the ropivacaine injection, with concentration determined by Dixon's up-and-down method as described in the intervention section, followed by the same assessments.
Patients should be counseled that antibacterial drugs including cefadroxil capsules should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When cefadroxil capsules are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefadroxil capsules or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Repackaged By / Distributed By: RemedyRepack Inc.

625 Kolter Drive, Indiana, PA 15701

(724) 465-8762
AIM: To investigate the impact of preoperative cardiovascular disease on the perioperative period of rectal cancer patients over 75 years old.
METHODS: The clinicopathological data of 625 elderly patients aged ≥ 75 years who underwent radical rectal cancer surgery in the Cancer Hospital of the Chinese Academy of Medical Sciences and affiliated Heji Hospital of Changzhi Medical College from January 2011 to December 2022 were retrospectively collected and analyzed. According to preoperative comorbidities, all patients were divided into cardiovascular disease group (n = 361) and non-cardiovascular disease group (n = 264). One hundred and ninety-two pairs were selected from each group through Propensity score-matched to further analysis. Perioperative indexes and postoperative complications were compared between the two groups.
RESULTS: There were no significant differences in clinicopathological data between the two groups (P > 0.05). The proportion of elderly patients with cardiovascular disease who went to ICU after radical surgery was significantly higher than those without cardiovascular disease (19.3% vs. 10.4%, P = 0.015). There was no significant difference between the two groups in the time to first flatus (3.0 vs. 3.5 days, P = 0.332) and postoperative hospital stay (11.3 vs. 10.5 days, P = 0.297). One patient in the cardiovascular disease group died due to pulmonary embolism. A total of 100 patients (26.0%) developed postoperative complications, and the incidence of overall complications (30.7% vs. 21.4%, P = 0.036) and grade 3-5 complications (12.5% vs. 6.3%, P = 0.036) in the cardiovascular disease group was significantly higher than that in the non-cardiovascular disease group. In terms of gastrointestinal disorders, the incidence of anastomotic leakage (6.8% vs. 2.1%, P = 0.026) in elderly patients with cardiovascular diseases was significantly higher than that in patients without cardiovascular disease. In addition, the incidence of cardiac disorders (8.3% vs. 2.6%, P = 0.014) in elderly patients with cardiovascular disease was significantly higher.
CONCLUSION: Elderly rectal cancer patients over 75 years old with cardiovascular disease are more likely to develop severe complications after radical surgery, especially anastomotic leakage and cardiac disorders.
AmDTx is a mindfulness-based meditation app that includes lessons, interactive exercises, and additional in-app features to practice mindfulness. Participants will receive a premium account for 1 year; the current study will evaluate outcomes over 3 months. The intervention will be delivered concurrently with treatment as usual which includes standard psychosocial care as participants are referred to their respective programs.
PURPOSE: To obtain the subject composition stably and homogeneously containing a basic local anesthetic agent and its hydrochloride and capable of exhibiting quick-acting and long-acting action on local mucous membrane or skin as an external preparation by blending the basic local anesthetic agent with its hydrochloride by a specific method. CONSTITUTION: This composition is obtained by dissolving or dispersing (A) a basic local anesthetic agent (e.g. lidocaine or dibucaine) into oil and fat or lipophilic base (e.g. coconut oil or Vaseline) miscible with the oil and fat. The blend of the component A with the component B is carried out so that a ratio of a coefficient obtained by dividing each amount of the components A and B by a maximum amount which is permissible in treated place is (7:3) to (2:3) and total sum of the coefficient becomes >=0.5. Furthermore, crotamiton, etc., is preferably used when the composition is oleagenous ointment or suppository or purified water, etc., is preferably used as the solvent for dissolving or dispersing the component B.
When performing actual transplantation into a body for the purpose of regenerative medicine, advanced safety measures are necessary in sterilization treatment or the packaging process, and a large burden is placed on a practitioner when a new material is to be utilized. Meanwhile, conventional collagen is even now being utilized for implantation in other applications, and the results of transplantation thereof are good. However, conventional collagen has not been shown to work effectively for curing nerve damage. Conventional LASCol has not been known to have a survival-maintaining effect on nerve cells. The nerve cell culture material including LASCol according to the present invention has the effect of suitably maintaining survival of nerve cells. The therapeutic agent for nerve cell damage including LASCol according to the present invention permeates or advantageously causes proliferation of endogenous nerve cells even in a living body, thereby enabling early extension and connection of neurites, and has an effect sufficient to produce an improved BBB score with respect to nerve damage.
PURPOSE:To provide the title composition improved in the in vivo solubility and absorbability of the medicine contained, containing an alginate of lowered viscosity and a poorly soluble medicine. CONSTITUTION:An alginate produced from naturally-occurring brown algae or microorganisms is first treated with a chemical such as acid or alkali and an enzyme such as alginic acid lyase to prepare an alginate of lowered viscosity 10-1500 (pref. 100-1200)cps in the viscosity determined using a Brookfield viscometer in the form of a 10wt.% solution at 20 deg.C. Thence, 1 pt.wt. of a poorly soluble medicine [pref. <=100 (esp. <=50mum)mum in average granular size] is formulated with 0.2-10 pts.wt. of the above alginate followed by grinding, thus obtaining the objective medicine composition. A broad range of medicines can be applied for the present purpose irrespective of their types.
A tetracycline dye salt is obtained by reacting an acid salt of tetracycline alone or together with an acid salt of one or more antibiotics having an amino salt forming group with an organic sulphonic acid dye salt approved for use in foods, drugs and cosmetics by the Food and Drug Administration of the United States and listed in The Merck Index, Sixth Edition, pages 1112-1116. The sulphonic acid salts have one, two or three acidic groups occupied by an alkali metal and form products in which one, two or three mols. of tetracycline are reacted as a salt with the sulphonic acid dye. Specified other antibiotics are chlortetracycline, oxytetracycline, neomycin and streptomycin. Typical dye salts are disodium 2,4-dinitro - 1 - naphthol - 7 - sulphonate, disodium 1 - pseudocumylazo - 2 - naphthol - 3,5 - disulphonate, trisodium 1 - (4 - sulpho - 1 - naphthylazo)-2-naphthol-3,6-disulphonate and trisodium 3 - carboxy - 5 - hydroxy - 1 - p - sulphophenyl-4-p-sulphophenyl-azopyrazole.ALSO:An aqueous tetracycline pharmaceutical preparation, which is stable and of good colour and taste, comprises tetracycline free base and a tetracycline dye salt obtained by reacting an acid salt of tetracycline with an organic sulphonic dye salt suitable for use in drugs and cosmetics and listed in The Merck Index, Sixth Edition, pages 1112-1116.  The tetracycline in the dye salt may be replaced in part by one or more antibiotics having amino salt forming groups, e.g. chlortetracycline, oxytetracycline, neomycin and streptomycin.  A suitable dye is obtained by reacting 1 or 2 mols. of an acid salt of tetracycline and 2 or 1 mols. of said other antibiotic with 1 mol. of an organic sulphonic acid dye salt.  The dye salt comprises 0.1 to 50% by weight of the total antibiotic activity.  Optional additions are antibacterial agents, antifungal agents, colours, flavours, alcohols, salts, buffers, dispersing agents and excipients.  Examples are given of (a) a syrup containing tetracycline, the tetracycline dye salt formed from trisodium salt of 1-(4-sulpho-1-naphthylazo) - 2 - naphthol - 3,6 - disulphonic acid, sucrose, monosodium phosphate, alcohol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate and flavour, (b) an aqueous suspension containing tetracycline, a tetracycline dye salt as in (a) and the other ingredients as in (a), the content of sucrose and tetracycline being lower than in (a).
Prior to surgery, patients undergo radiation therapy boost over 4 fractions. Patients then undergo standard of care surgery 1-3 weeks from the last day of boost. 3 to 5 weeks after surgery, patients continue standard of care WBI in the absence of disease progression or unacceptable toxicity.
For the Yes and Know study, cohorts of 5-15 participants will be recruited and randomized into one of the two study conditions: Yes and Know: Life Skills intervention (intervention condition) or Yes and Know: Nutrition Skills intervention (comparison condition). The programs will be delivered by trained health educators through synchronous virtual sessions. Participants can access the supplemental resources and activities for their respective programs on the program's website. Each cohort will be recruited from a local partner site (with a focus on rural communities in the South and Southeast regions of the United States), and young people must have consent and provide their assent to be part of the study. Yes and Know: Sexual Health and Life Skills covers sexual and reproductive health, healthy relationships, life skills, and educational and career success. Yes and Know: Nutrition Skills covers learning to make healthy decisions about food, weight and disordered eating, and creating nourishing meals. Both programs consist of nine 60-minute synchronous group sessions, totaling nine hours, to be taught at least once a week (or more frequently depending on sites' scheduling).
Patients with renal or hepatic impairment should be treated with titrated oral risperidone prior to initiating treatment with RYKINDO [see Use in Specific Populations (8.6, 8.7) and Clinical Pharmacology (12.3)]. The recommended starting dose is 0.5 mg oral risperidone twice daily during the first week, which can be increased to 1 mg twice daily or 2 mg once daily during the second week. If a total daily dose of at least 2 mg oral risperidone is well tolerated, RYKINDO 25 mg can be administered every 2 weeks with oral supplementation for 7 days following the first injection [see Dosing and Administration (2.2, 2.3)]. In some patients, slower titration may be appropriate. Alternatively, a starting dose of RYKINDO 12.5 mg may be appropriate. The efficacy of the 12.5 mg dose has not been investigated in clinical trials.
Neuroinflammation caused by microglia in the central nervous system (CNS) is observed after myocardial infarction (MI). However, the inflammatory response mechanism remains unclear. BuChang Naoxintong capsule (NXT) is a Chinese medicine for treating ischemic cardio-cerebrovascular diseases, requiring more studies to understand the pharmacodynamic mechanism. Permanent ligation of the left anterior descending coronary artery (LAD) was performed in rats. Additionally, histopathological staining in the left ventricular (LV) and immunofluorescence within the brain cortex after 1 d and 7 d of MI were performed to determine the NXT pharmacodynamic action and best administration dosage. Proteomics helped obtain the essential proteins related to neuroinflammation and MI in the heart and brain tissue after 7 d of MI. Based on TTC, HE, Masson, and immunofluorescence staining results of CD206 and IBA-1, NXT demonstrated a better pharmacodynamic action towards myocardial injury and neuroinflammation after 7 d of MI. Moreover, the human equivalent dosage of NXT (220 mg/kg) became the best administration dose. The proteome bioinformatics analysis in the LV and brain cortex was performed. Thus, the elongation of very long-chain fatty acids protein 5 (ELOVL5) and ATP-binding cassette subfamily G member 4 (ABCG4) became critical proteins related to MI and neuroinflammation. The western blotting results indicated that ABCG4 expression possessed the same trend as the proteomics results. The auto-dock results revealed that ABCG4 had a good binding ability with Ferulic acid, Paeoniflorin, and Tanshinone II A, the key ingredients of NXT. The cellular thermal shift assay results demonstrated that ABCG4 showed better thermal stability post-NXT treatment. NXT can improve myocardial injury, such as heart infarct size, pathological injury, myocardial fibrosis, and inflammatory cell infiltration. Additionally, brain neuroinflammation induced by microglia after MI affects the expression and structure of ABCG4. Thus, ABCG4 could be the key protein associated with MI and neuroinflammation.
PURPOSE: Transcutaneous spinal cord stimulation (TSCS) is a novel neuromodulation modality developed to promote functional restoration in patients with neurological injury or disease. Previous pilot data suggest that lower urinary tract dysfunction (LUTD) due to stroke may be partially alleviated by TSCS. In this study, we examine the mechanism of this effect by evaluating bladder-related brain activity in patients before and after TSCS therapy and comparing it to healthy volunteers.
MATERIALS AND METHODS: Patients who developed storage LUTD after a stroke and healthy volunteers without LUTD were recruited. Patients and healthy volunteers underwent simultaneous urodynamics and functional MRI. Patients then completed 24 biweekly sessions of TSCS and underwent another simultaneous urodynamics-functional MRI study. Clinical outcomes were assessed using validated questionnaires and voiding diary.
RESULTS: Fifteen patients and 16 healthy volunteers completed the study. Following TSCS, patients exhibited increased blood-oxygen-level-dependent activity in areas including periaqueductal grey, the insula, the lateral prefrontal cortex, and motor cortex. Prior to TSCS therapy, healthy controls exhibited higher blood-oxygen-level-dependent activity in 17 regions, including multiple regions in the prefrontal cortex and basal ganglia. These differences were attenuated after TSCS with no frontal brain differences remaining between healthy volunteers and stroke participants who completed therapy. Neuroimaging changes were complemented by clinically significant improvements in questionnaire scores and voiding diary parameters.
CONCLUSIONS: TSCS therapy modulated bladder-related brain activity, reducing differences between healthy volunteers and stroke patients with LUTD. These changes, alongside improved clinical outcomes, suggest TSCS as a promising approach for LUTD management.
The efficacy of TIVORBEX for the treatment of acute pain was demonstrated in two multicenter, randomized, double-blind, placebo-controlled, parallel arm studies comparing TIVORBEX 20 mg three times daily, 40 mg twice daily, 40 mg three times daily, and placebo in patients with pain following bunionectomy (Study 1 and Study 2). The two studies enrolled a total of 835 patients with a mean age of 40 years (range 18 to 68 years) a minimal pain intensity rating of at least 40 mm on a 100-mm visual analog scale (VAS) during the 9-hour period after discontinuation of the anesthetic block following bunionectomy surgery. Patients were randomized equally across the treatment groups. 

The mean pain intensity measured by VAS at baseline for all treatment groups in both studies ranged from 71 to 74 mm. One tablet of hydrocodone/acetaminophen 10 mg/325 mg was permitted every 4 to 6 hours as rescue medication. There was a greater use of concomitant opioid rescue medication in placebo-treated patients than in TIVORBEX-treated patients. In Study 1, 89% of patients in the TIVORBEX 20 mg three times daily group, 90% of the patients in the TIVORBEX 40 mg twice daily group, 82% in the TIVORBEX 40 mg three times daily group, and 97% of patients in the placebo group took rescue medication for pain management during the study. In Study 2, 87% of patients in the TIVORBEX 20 mg three times daily group, 76% of the patients in the TIVORBEX 40 mg twice daily group, 80% in the TIVORBEX 40 mg three times daily group, and 89% of patients in the placebo group took rescue medication for pain management during the study.

The average pain intensities over time are depicted for the treatment groups in Figure 1 for Study 1 and Figure 2 for Study 2. In both studies, TIVORBEX Capsules 20 mg three times daily, 40 mg twice daily and 40 mg three times daily, demonstrated efficacy in pain intensity reduction compared with placebo, as measured by the sum of pain intensity difference over 0 to 48 hours after the first dose.

Figure 1 Average Pain Intensity Over 48 Hours for TIVORBEX and Placebo Groups – Study 1

Figure 2 Average Pain Intensity Over 48 Hours for TIVORBEX and Placebo Groups – Study 2
Sorafenib, 400 mg orally, 2 tablets (200 mg each) bid (bis in die \[twice daily\]) on Study Days 2 to 19 + Paclitaxel (225 mg/m\^2 iv \[Intravenous\]) and Carboplatin (AUC \[area under the curve\] 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.